A list of targets and developmental opportunities19 Aug 2024 20:35
scib2, scancell’s second immunobody® therapy, targets an antigen called ny-eso-1, which is expressed on a range of solid tumours, including nsclc and oesophageal, ovarian, bladder and prostate cancers, as well as neuroblastoma, melanoma and sarcoma. scancell’s studies have demonstrated that administration of scib2 dna payload as a liposomal nanoparticle results in potent immune responses and anti-tumour activity in preclinical models
as iscib1+ is very similar to scib1 it is anticipated that it should show the same exceptional results as scib1 with an objective response rate of 85% but in a broader range of melanoma patients.
scancell has used its glymab® technology to generate a series of high affinity mabs targeting glycans that are over-expressed on cancer cells. the portfolio currently includes five mab candidates; four targeting different cancers and one t-cell targeting antibody. each mab has high specificity for particular glycan molecules, making them attractive development candidates. although scancell’s initial focus is on pancreatic, lung, colorectal and gastric cancers, the individual glycans are also expressed on other tumour types which would broaden their potential utility to other indications.
sc129: specific for the sialyl-di-lewisa glycan, a target for pancreatic cancer
sc134: specific for fucosyl gm1, a target for small cell lung cancer
sc88: specific for the lewisacx glycan, a target for colorectal cancer
sc27: specific for the lewisy glycan, a target for gastric cancer
sc2811: specific for ssea4 on human and mouse t cells with stem-like properties – a target for any solid tumour
application of the avidimab® modifications to enhance non-covalent interactions between target-bound antibody molecules renders the antibodies capable of direct cell killing without the need for the complement system or immune effector cells, thereby increasing their potency.
in addition to being potential therapies in their own right, the specificity of the anti-glycan mabs enables their development into a range of antibody-based therapies with differing mechanisms of action, including:
antibody drug conjugates (adc) for the delivery of cytotoxic drugs, immunotoxins or radionuclide agents.
redirection of t cells using t cell - engaging bispecific antibodies to enhance immune-mediated anti-cancer therapeutic effects.
the versatility of scancell’s current anti-glycan mab portfolio, combined with the potential for continued expansion using the enabling glymab® technology platform and the potential application of avidimab® to any mab, creates wide-ranging co-development and licencing opportunities.
modi 2
a list of specific ****citrullinated peptides have now been selected for clinical development as the modi-2 vaccine, that have the potential to address different cancer indications to modi-1, including tumours with a particularly immunosuppresive environments colon cancer, renal cell carcinoma and colorectal cancer
Sign In
Follow the stocks
